Search
. Advanced search

Article


More than 750 million Animal Health pipettes from Kiel

Successful medium-sized company in Kiel certified according to stringent FDA standards
13. October 2004
750 Millionen Pipetten mit flüssigen Tierarzneimitteln, davon allein 500 Millionen des Antiflohmittels Advantage hat die KVP Pharma + Veterinärprodukte GmbH, eine 100-prozentige Bayer HealthCare-Tochtergesellschaft in Kiel, seit ihrer Gründung vor 30 Jahren produziert. Rund 50 Prozent aller von der Bayer HealthCare AG in der Welt vertriebenen Tierarzneimittel kommen aus Kiel.750 Millionen Pipetten mit flüssigen Tierarzneimitteln, davon allein 500 Millionen des Antiflohmittels Advantage hat die KVP Pharma + Veterinärprodukte GmbH, eine 100-prozentige Bayer HealthCare-Tochtergesellschaft in Kiel, seit ihrer Gründung vor 30 Jahren produziert. Rund 50 Prozent aller von der Bayer HealthCare AG in der Welt vertriebenen Tierarzneimittel kommen aus Kiel.

Kiel, October 13, 2004 – This year KVP Pharma + Veterinär Produkte GmbH, a wholly owned subsidiary of Bayer HealthCare AG, is celebrating the 30th anniversary of its founding. The Kiel-based company's employees can take pride in having manufactured more than 750 million pipettes containing liquid animal health products, including over 500 million pipettes of the antiflea product Advantage®. Yet the KVP workforce has another reason to celebrate, as the production facility has now been certified according to the stringent guidelines of the United States Food and Drug Administration (FDA). The local authorities in Kiel inspect these standards every two years according to Good Manufacturing Practice (GMP) guidelines. Until 1973, the 170 employees of the former Mimosa factory in Kiel-Projensdorf manufactured black-and-white photographic paper. Agfa-Gevaert AG then decided to close the plant on the Kiel Canal however. Yet instead of shutting down the facility, Bayer in 1974 initially gave 26 employees at the site a new opportunity with the production of veterinary health products. Over the past 30 years, more than 1.2 billion tablets and over 30,000 metric tons of liquids have been produced at the Kiel site. If lined up one after another, all the pipettes of animal health products manufactured so far would stretch around the Earth. Today more than 360 KVP employees produce about 50 percent of all animal health products sold by Bayer worldwide. With a medium-sized, independent corporate structure, KVP is the biggest manufacturing and logistics site of Bayer HealthCare AG's Animal Health Division – a market that enjoys steady growth rates in both Europe and (North) America." In the past 10 years alone, we have increased the size of our workforce from 260 to more than 360. Thus we are a permanent fixture of both the labor market in Kiel and the vocational training market," says Olaf Assenheimer, who became Managing Director of KVP GmbH in 2002. Assenheimer describes his company as a "successful, competitive, medium-sized international supplier from Kiel – backed by a strong parent company." Adds Assenheimer confidently: "The FDA certification will allow us to secure and expand our competitive position in the very important U.S. market and to continue our success story." KVP supplies more than 100 countries around the world with 150 products in about 800 presentations as animal health products and also with veterinary nutrition and grooming products. From ointments, creams and pastes through tablets, powders and granules to liquids, suspensions, emulsions and aerosols: KVP has a perfect command of both production and the important logistics process. The company directly ships essential products to veterinarians in Germany within 24 hours. Among the products manufactured by KVP are: Advantage® pipettes for spot-on antiparasitic treatment; the non-prescription antibiotic Baytril®; Baycox® to fight infections in small and large animals; Drontal and Droncit to control worms in dogs and cats; Kiltix® collars to control fleas and ticks in dogs and cats; the Bolfo® range to combat parasites in pets; Bayvarol® to control mites in bees; Rintal® against endoparasites; and Sebacil® and Asuntol® against ectoparasites. "The diversification of our products is both a challenge and an advantage," explains Assenheimer. "We have to – and are able to – ensure a high level of flexibility for our plants, apparatus and technologies, as well as complex quality control systems, careful documentation and compliance with very stringent hygiene rules. Our logistics experts can ensure the desired shipment directly to customers within a very short period of time." KVP is well equipped to handle further successful corporate development in Schleswig-Holstein: this year the company increased its vocational training capacity by 60 percent and is currently seeking school students to join its training programs in 2005. KVP trains chemical and pharmaceutical laboratory assistants and mechanical electricians, and in 2004 also added training opportunities for storage logistics experts. Pharmaceutical and pharmaceutical engineering students also regularly participate in internships at KVP in order to become acquainted at an early stage with the diverse aspects of employment in a pharmaceutical company. Sums up Assenheimer: "The continuous and voluntary improvement of our high standards in the fields of environmental protection and safety is a matter of course for us – as is the qualification and advancement of both long-serving and new employees."

In reizvoller Lage am Nord-Ostsee-Kanal in Kiel produziert auf einem Gelände von rund neun Hektar die 100-prozentige Bayer HealthCare-Tochtergesellschaft KVP Pharma + Veterinär Produkte GmbH mit über 360 Mitarbeitern Tierarzneimittel. Die Bayer HealthCare AG gehört mit einem Umsatz von 790 Millionen Euro (2003) weltweit zu den führenden Anbietern auf dem Tiergesundheitsmarkt.In reizvoller Lage am Nord-Ostsee-Kanal in Kiel produziert auf einem Gelände von rund neun Hektar die 100-prozentige Bayer HealthCare-Tochtergesellschaft KVP Pharma + Veterinär Produkte GmbH mit über 360 Mitarbeitern Tierarzneimittel. Die Bayer HealthCare AG gehört mit einem Umsatz von 790 Millionen Euro (2003) weltweit zu den führenden Anbietern auf dem Tiergesundheitsmarkt.
In reizvoller Lage am Nord-Ostsee-Kanal in Kiel produziert auf einem Gelände von rund neun Hektar die 100-prozentige Bayer HealthCare-Tochtergesellschaft KVP Pharma + Veterinär Produkte GmbH mit über 360 Mitarbeitern Tierarzneimittel. Die Bayer HealthCare AG gehört mit einem Umsatz von 790 Millionen Euro (2003) weltweit zu den führenden Anbietern auf dem Tiergesundheitsmarkt.In reizvoller Lage am Nord-Ostsee-Kanal in Kiel produziert auf einem Gelände von rund neun Hektar die 100-prozentige Bayer HealthCare-Tochtergesellschaft KVP Pharma + Veterinär Produkte GmbH mit über 360 Mitarbeitern Tierarzneimittel. Die Bayer HealthCare AG gehört mit einem Umsatz von 790 Millionen Euro (2003) weltweit zu den führenden Anbietern auf dem Tiergesundheitsmarkt.


Copyright © Bayer HealthCare AG